eFFECTOR Therapeutics Inc (NASDAQ:EFTR) Given Consensus Rating of “Buy” by Brokerages

Shares of eFFECTOR Therapeutics Inc (NASDAQ:EFTR) have received an average rating of “Buy” from the six brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $28.60.

Several equities analysts have commented on EFTR shares. Zacks Investment Research cut shares of eFFECTOR Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, January 10th. Stifel Nicolaus raised shares of eFFECTOR Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Monday, November 8th. Credit Suisse Group started coverage on shares of eFFECTOR Therapeutics in a research note on Tuesday, October 12th. They set an “outperform” rating and a $20.00 target price on the stock. Mizuho started coverage on shares of eFFECTOR Therapeutics in a research note on Monday, October 4th. They set a “buy” rating and a $20.00 target price on the stock. Finally, JMP Securities began coverage on shares of eFFECTOR Therapeutics in a research note on Tuesday, September 21st. They set an “outperform” rating and a $33.00 target price on the stock.

In related news, Director Jonathan D. Root sold 8,113 shares of the firm’s stock in a transaction that occurred on Thursday, December 2nd. The shares were sold at an average price of $5.68, for a total transaction of $46,081.84. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jonathan D. Root sold 28,785 shares of the firm’s stock in a transaction that occurred on Tuesday, November 9th. The shares were sold at an average price of $11.00, for a total transaction of $316,635.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 297,552 shares of company stock valued at $2,481,782.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC bought a new position in eFFECTOR Therapeutics during the third quarter valued at approximately $187,000. Jane Street Group LLC bought a new position in shares of eFFECTOR Therapeutics in the third quarter valued at approximately $257,000. Geode Capital Management LLC bought a new position in shares of eFFECTOR Therapeutics in the third quarter valued at approximately $337,000. Verition Fund Management LLC bought a new position in shares of eFFECTOR Therapeutics in the third quarter valued at approximately $347,000. Finally, Sectoral Asset Management Inc bought a new position in shares of eFFECTOR Therapeutics in the third quarter valued at approximately $40,503,000. 58.13% of the stock is currently owned by hedge funds and other institutional investors.

EFTR stock opened at $7.25 on Monday. eFFECTOR Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $40.42. The business has a 50-day moving average price of $7.93.

eFFECTOR Therapeutics (NASDAQ:EFTR) last released its earnings results on Monday, November 8th. The company reported $0.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.68. The company had revenue of $0.43 million for the quarter. Analysts expect that eFFECTOR Therapeutics will post -0.55 earnings per share for the current year.

About eFFECTOR Therapeutics

Locust Walk Acquisition Corp. entered into a definitive business combination agreement with eFFECTOR Therapeutics Inc

Featured Article: Equity Income

Analyst Recommendations for eFFECTOR Therapeutics (NASDAQ:EFTR)

Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.